Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Cloretazine in elderly patients with de novo poor-risk acute myelogenous leukemia
2006-001853-89Phase 2Completed
- Sponsor
- Vion Pharmaceuticals
- Start
- May 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of laromustine in acute myeloid leukemia (AML), sponsored by Vion Pharmaceuticals. Primary endpoint: Complete response rate. Started May 2006; status: completed.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-001853-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001853-89.